Insider buying last 90 days
No open-market insider purchases were filed for ALVO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ALVO insider filing, plotted on the chart in Gekko.Open ALVO in Gekko
NASDAQ: ALVO
Alvotech (ALVO) Stock Analysis & Forecast
Oct 12 close
$5.50−0.28 (−4.8%)
Gekko Brief
AI summaryOct 12 closeAlvotech's week centers on a long-term manufacturing partnership with LOTTE Biologics, under which LOTTE will produce drug substance for multiple antibody biosimilars at its Syracuse, New York facility, expanding Alvotech's US-based manufacturing footprint and global supply network. The company also released its half-yearly financial report, showing a net loss of $65.8 million for the six months ended June 30, 2026, compared with a net profit of $141.7 million in the prior-year period, attributed primarily to lower non-cash fair value gains on derivative financial instruments. Separate commentary has framed the stock as potentially undervalued following the manufacturing updates.
Shares closed at $5.50, down 4.8% on the day, but remain above both the 50-day average of $5.02 and the 200-day average of $4.21, with the 50-day above the 200-day. The GekkoIndex reading of 57.1 places the stock in the Neutral zone, up 5.8 over the past five sessions. Price sits 3.8% below Gekko Fair Value of $5.72.
Alvotech's next earnings report is scheduled for 11 November 2026, before the open, 29 days out and beyond a typical 20-trading-day hold; the prior report on 19 August showed an EPS miss against estimate with an 8.1% reaction. No insider, Congress or unusual options activity appears in the current window. Seasonality from this point has averaged a 11.6% decline over the next 20 trading days across 4 years, with no positive instances, a pattern worth noting alongside analyst consensus of 3 buy ratings and a $6.80 price target.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Alvotech price vs fair value
Close $5.50200-day averageGekko Fair Value $5.72
Alvotech quick facts
- Market cap
- $1.86B
- P/E ratio
- —
- Forward P/E
- 15.2
- EPS, TTM
- −$0.62
- Revenue, TTM
- $494.6M
- Profit margin
- -36.3%
- Dividend yield
- —
- Beta
- 0.21
- Volume
- 839,892 avg 1.35M
- 1-year return
- −33.7%
- Typical daily move
- ±6.4%
- Typical 20-day move
- ±10%
- 50-day average
- $5.02
- 200-day average
- $4.21
- Next earnings
- Nov 11 before open
- Shares outstanding
- 356.8M
Alvotech swing-trade checklist
Alvotech scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $5.50 is above the 50-day ($5.02) and 200-day ($4.21) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
57.1, Neutral
Reading 57.1 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
3.8% below
Price is within 5% of Gekko Fair Value (3.8% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Nov 11, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−11.6% on average
From this point in the calendar, the next 20 trading days averaged −11.6% over 4 years, rising in 0 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Alvotech stock chart and price history
Alvotech closed at $5.50 on Oct 12, 2026, −33.7% over the past year, inside a 52-week range of $2.94 to $9.05.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +4.0%
- 3 months
- +66.7%
- 6 months
- +48.2%
- 1 year
- −33.7%
The full ALVO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ALVO in Gekko
Follow Alvotech through every session
Put ALVO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ALVO in GekkoFree for 7 days. No credit card required.
Alvotech GekkoIndex: the smart money zone
Alvotech’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.1, in the Neutral zone, up 5.8 points over five sessions.
57.1Neutral
Up 5.8 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 55 | 0.0% | −1.7% | ||
| Accumulation | 289 | +0.6% | +2.3% | ||
| Neutral (current zone) | 288 | −1.4% | −6.2% | ||
| Distribution | 41 | +0.6% | +1.0% | ||
| Selling | 9 | Too few readings yet | |||
Average ALVO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ALVO price, zone by zone.Track ALVO in Gekko
Is Alvotech stock overvalued? Gekko Fair Value
Alvotech trades 3.8% below Gekko Fair Value of $5.72, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Alvotech shares are worth, recalculated every trading day.
$5.72
Gekko Fair Value, Oct 10, 2026
3.8% below fair value · About fair value
At the end of Aug 2026 the price was 0.8% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ALVO in Gekko
Alvotech insider and Congress trading
No open-market insider purchases were filed for Alvotech, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ALVO were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ALVO, plotted on the chart in Gekko.Open ALVO in Gekko
Buybacks
Alvotech has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2024
- $4.24M
- As a share of market cap
- 0.23%
From company filings.
Alvotech earnings: next date and track record
Alvotech reports on Nov 11, 2026, before the open (30 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 11, 2026
Expected before the open, 30 days away
- EPS estimate
- −$0.03
- Revenue estimate
- $136.8M
3 of 8reports beat the EPS estimate
±8.1%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 19, 2026 AI summary
- What they said
- Alvotech reported Q2 2026 results marked by a production slowdown due to significant manufacturing facility and quality system investments enabling BLA resubmissions for AVT05 and AVT06 in June. FDA closed the May surveillance inspection with a favorable VAI classification. The company now has 5 biosimilars generating revenue (Humira, STELARA, Simponi, EYLEA, Prolia/Xgeva biosimilars). A June equity offering raised ~$165 million gross proceeds from 20 new institutional investors.
- Guidance
- Management expects a strong Q4 2026 as manufacturing returned to planned levels end of Q2 and order book is strong. FDA approvals for AVT05 (Simponi biosimilar) and AVT06 are anticipated in Q4 2026, positioning Alvotech among first-wave biosimilar entrants.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 19, 2026 | −$0.11 est −$0.06 | $106.0M est $103.0M | +8.1% |
| Mar 18, 2026 | −$0.37 est −$0.01 | $173.2M est $162.2M | −6.3% |
| Nov 12, 2025 | −$0.02 est $0.04 | $114.0M est $164.9M | −1.1% |
| Aug 13, 2025 | $0.03 est $0.00 | $173.2M est $155.6M | −2.0% |
| May 7, 2025 | $0.35 est $0.03 | $132.8M est $120.5M | +17.7% |
| Mar 26, 2025 | −$0.24 est −$0.03 | $151.2M est $97.99M | −11.1% |
| Nov 13, 2024 | −$0.48 est −$0.06 | $489.7M est $85.00M | −0.7% |
| Aug 15, 2024 | $0.28 est −$0.02 | $198.8M est $84.00M | +17.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Alvotech stock forecast and analyst price targets
Analysts’ average 12-month price target for Alvotech is $6.80, +23.6% from the last close, from 3 firms rating the stock in the last 90 days.
$6.80consensus 12-month target, +23.6% from the last close
Now $5.50Avg $6.80
Low $6High $8
Each firm’s latest rating in the last 90 days: 3 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Bank of America Securities | $7 | +27.3% |
| Sep 16 | Barclays | $8 | +45.5% |
| Aug 24 | UBS | $6 | +9.1% |
| Aug 24 | Bank of America Securities | $7 | +27.3% |
| Aug 21 | UBS | $6 | +9.1% |
−6.2%average 20-day move after past Neutral readings
−11.6%average move over the next 20 trading days in the last 4 years
±6.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Alvotech seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Alvotech averaged −11.6% across the last 4 years, rising in 0 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.6% | 2 of 4 |
| Next 10 trading days | −3.1% | 1 of 4 |
| Next 15 trading days | −4.7% | 0 of 4 |
| Next 20 trading days | −11.6% | 0 of 4 |
| Next 30 trading days | −12.8% | 0 of 4 |
For scale, ALVO’s typical 20-trading-day move in either direction is about 10%.
Alvotech market cap and key statistics
Alvotech’s market cap is $1.86B and revenue of $494.6M over the last twelve months.
Valuation
- Market cap
- $1.86B
- Forward P/E
- 15.2
- EPS, TTM
- −$0.62
- Gekko Fair Value
- $5.72
Trading
- Volume
- 839,892
- Avg volume, 20 days
- 1.35M
- 52-week high
- $9.05
- 52-week low
- $2.94
- Shares outstanding
- 356.8M
Financials
- Revenue, TTM
- $494.6M
- Profit margin
- -36.3%
- Return on equity
- 0%
- Quarterly earnings growth, YoY
- −99.0%
Risk and income
- Beta
- 0.21
- Typical daily move
- ±6.4%
- Typical 20-day move
- ±10%
Alvotech stock news this week
Coverage of Alvotech this week reads positive: 17 positive, 4 neutral and 0 negative headlines.
- LOTTE Biologics and Alvotech Forge Long-Term Partnership to Expand Global Biosimilar Manufacturing CapacityBioPharma APAC, Oct 12
- Alvotech : Half yearly fcial & audit reports / ltd reviews - 2026 Half yearly financial report (revised) - ENwww.marketscreener.com, Oct 12
- Korea's LOTTE Biologics inks US-based manufacturing agreement with Alvotech to increase global supplyBioSpectrum Asia, Oct 9
- Alvotech (ALVO) Could Be 14% Undervalued On Manufacturing Capacity UpdatesYahoo! Finance Canada, Oct 9
- LOTTE Biologics and Alvotech announce US-based manufacturing agreement to increase global supplyJapan Wire by Kyodo News, Oct 9
- Alvotech (ALVO) Expands With LOTTE As Its Undervalued Narrative Faces A Fresh TestSimply Wall Street, Oct 8
Alvotech peers
Alvotech’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Alvotech stock FAQ
What is Alvotech’s market cap?
Alvotech’s market cap is $1.86B at the Oct 12, 2026 close of $5.50, with 356.8M shares outstanding.
What is the Alvotech stock forecast?
The consensus analyst 12-month price target for Alvotech is $6.80, +23.6% from the last close. Of the 3 firms that rated the stock in the last 90 days, 3 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Alvotech stock overvalued or undervalued?
On Gekko’s estimate Alvotech is about fair value: the Oct 12, 2026 close of $5.50 is 3.8% below Gekko Fair Value of $5.72. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Alvotech report earnings next?
Alvotech is expected to report on Nov 11, 2026, before the market opens (30 days away). Analysts expect earnings of −$0.03 per share on revenue of $136.8M. Alvotech beat the earnings estimate in 3 of its last 8 reports, moving 8.1% on average across the report.
What is Alvotech’s 52-week high and low?
Alvotech’s 52-week high is $9.05 and its 52-week low is $2.94; it closed at $5.50 on Oct 12, 2026, −33.7% over the past year. Over the last five years the shares peaked at $18.00 on Feb 26, 2024.
Is Alvotech stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Alvotech the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.